Skip to main content
MADRIGAL PHARMACEUTICALS, INC. logo

MADRIGAL PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · MDGL ISIN · US5588681057 LEI · 549300CHIMT2EUSNJB60 US Manufacturing
Filings indexed 1,022 across all filing types
Latest filing 2023-11-21 Major Shareholding Noti…
Country US United States of America
Listing US MDGL

About MADRIGAL PHARMACEUTICALS, INC.

https://www.madrigalpharma.com/

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious and progressive liver disease with high unmet medical need. The company's research led to the first U.S. Food and Drug Administration (FDA)-approved treatment for MASH. Madrigal's therapeutic goal is to halt or reverse liver scarring (fibrosis) and resolve the disease before patients experience severe complications, including cirrhosis, liver failure, and the need for transplantation.

Recent filings

Filing Released Lang Actions
SC 13D/A
Major Shareholding Notification
2023-11-21 English
FORM 4 SUBMISSION
Director's Dealing
2023-11-15 English
4 Filing
Director's Dealing
2023-11-15 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-11-13 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 6, 2023, by Madrigal Pharmaceuticals, Inc. It announces the issuance of a press release containing the company's financial results for the fiscal quarter ended September 30, 2023. The document itself does not contain the financial results but references the press release as an exhibit. The length is 3660 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the earnings release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER).
2023-11-06 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.